You are here

Article Text

Article menu

Download PDFPDF

Editorial
Role of drug eluting stents in diabetic patients
Free
  1. F Boccara1,
  2. E Teiger2,
  3. A Cohen1
  1. 1Department of Cardiology, Saint Antoine University Hospital. Assistance Publique-Hôpitaux de Paris and Université Paris VI, Paris, France
  2. 2Department of Physiopathology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris and Université Paris XII, Creteil, France
  1. Correspondence to:
    Dr Franck Boccara
    Cardiology department, Saint-Antoine University and Medical School, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie (Paris VI), 184, rue du faubourg Saint-Antoine, 75571 Paris Cedex 12, France; franck.boccara{at}sat.aphp.fr

Abstract

There is a clear need for a large multicentre trial comparing the efficacy of the two available drug eluting stents, sirolimus and paclitaxel, in diabetic patients with multivessel disease

  • BMS, bare metal stents
  • CABG, coronary artery bypass graft surgery
  • CI, confidence interval
  • DES, drug eluting stents
  • MACE, major adverse cardiac events
  • MI, myocardial infarction
  • OR, odds ratio
  • PCI, percutaneous coronary intervention
  • coronary artery disease
  • diabetes
  • drug eluting stents

https://doi.org/10.1136/hrt.2005.082172

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Published Online First 31 January 2006

    Linked Articles